Biontech Se 6-K Filing
Ticker: BNTX · Form: 6-K · Filed: Nov 26, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Nov 26, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Biontech Se (ticker: BNTX) to the SEC on Nov 26, 2025.
How long is this filing?
Biontech Se's 6-K filing is 1 pages with approximately 332 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 332 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-11-26 16:33:38
Filing Documents
- d16834d6k.htm (6-K) — 11KB
- d16834dex991.htm (EX-99.1) — 28KB
- g16834g1125134006995.jpg (GRAPHIC) — 3KB
- 0001193125-25-300670.txt ( ) — 43KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On November 26, 2025, BioNTech SE (the "Company") issued a press release announcing the results of the CureVac N.V. ("CureVac") extraordinary general meeting and the calculation of the exchange ratio in connection with its exchange offer for all outstanding shares of CureVac. A copy of the press release is attached hereto as Exhibit 99.1. This report on Form 6-K shall be deemed to be filed and incorporated by reference in the Company's registration subsequently filed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Prof. Dr. Ugur Sahin By: /s/ Dr. Sierk Poetting Name: Prof. Dr. Ugur Sahin Name: Dr. Sierk Poetting Title: Chief Executive Officer Title: Chief Operating Officer Date: November 26, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025 at 9:00 a.m. Eastern Time Expiration